{"id":"NCT03020082","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","briefTitle":"Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III","officialTitle":"A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2017-05","completion":"2017-05","firstPosted":"2017-01-13","resultsPosted":"2021-03-23","lastUpdate":"2021-03-23"},"enrollment":141,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C"],"interventions":[{"type":"DRUG","name":"Danoprevir","otherNames":["ASC08"]},{"type":"DRUG","name":"Ritonavir","otherNames":[]},{"type":"DRUG","name":"peginterferon alfa-2a","otherNames":["Peg-IFN"]},{"type":"DRUG","name":"RBV","otherNames":["RibasphereÂ®"]}],"arms":[{"label":"Danoprevir, Ritonavir, Peg-IFN,RBV","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.","primaryOutcome":{"measure":"Proportion of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"12 weeks","effectByArm":[{"arm":"Danoprevir, Ritonavir, Peg-IFN,RBV","deltaMin":136,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["31608213"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":141},"commonTop":["Anemia","Fever"]}}